Moderna has become the newest member of the UK’s pharmaceutical industry body, the Association of the British Pharmaceutical Industry (ABPI), building on the long-term commitment by the American-based company to expand its footprint and investment in the UK.
Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reportedly has ‘high ambitions’ for rapid global growth. Key to these ambitions will be a new vaccine research, development and manufacturing facility in the UK, creating new jobs and building up the UK’s life sciences ecosystem.
Darius Hughes, UK General Manager, Moderna, said: “This alliance is an important part of our long-term commitment to the UK and supports the wider significant investments in manufacturing, research and development we are making in this country.”
Richard Torbett, Chief Executive, ABPI, said: “With Moderna’s help we will be in an even stronger position to make the UK the best place in the world to research, develop and use new medicines and vaccines.”
